Heyholder
‹ Activism Filings

EyeGene,Inc Q3 operating loss of KRW 2.5 billion on revenue of KRW 1.2 billion

EyeGene,Inc· Periodic Report

AI summary · Not investment advice

In Q3, the company sold KRW 1.2 billion worth and lost KRW 2.5 billion from its main business, versus KRW 1.1 billion in sales and a KRW 1.6 billion loss a year earlier.

Operating profit · 3 months

KRW -2.5 billion

Key facts

Revenue (3 months)
KRW 1.2 billion
Net income (3 months)
KRW -2.3 billion
Period
Q3 (cumulative 2026.01.01 ~ 2026.09.30)
Revenue (prior-year 3 months)
KRW 1.1 billion
Revenue (year to date)
KRW 3.8 billion
Operating profit (prior-year 3 months)
KRW -1.6 billion
Operating profit (year to date)
KRW -10.0 billion
Net income (prior-year 3 months)
KRW -1.6 billion
Net income (year to date)
KRW -9.7 billion

Commentary

AI commentary · Not investment advice

What happened

Aegis Inc. (Eyegene) filed its quarterly report with consolidated results for the third quarter of 2026. Sales for the 3 months were KRW 1.17 billion. That is 6.1% higher than the same 3 months a year earlier and 13.0% lower than the previous quarter.

In the company's terms

Operating profit (profit from the core business) for the 3 months was a loss of KRW 2.51 billion. A year earlier it was a loss of KRW 1.65 billion. Net income for the 3 months was a loss of KRW 2.33 billion. A year earlier it was a loss of KRW 1.57 billion.

What changes for shareholders

For the year to date (January 1 to September 30), sales were KRW 3.78 billion. The operating loss was KRW 9.99 billion. The net loss was KRW 9.73 billion.

Comments

No comments yet

Comments from shareholders will appear here.